What is ElevateBio?
Founded in 2019 and headquartered in Cambridge, Massachusetts, ElevateBio operates as a unique platform for developing and commercializing cell and gene therapies. The company collaborates with innovative scientists and inventors to build a diverse portfolio of therapeutic ventures. Its strategy involves leveraging scientific breakthroughs to address unmet medical needs, positioning it as a key player in the advancement of regenerative medicine and personalized therapeutics. The scale of its funding indicates a growth-oriented strategy aimed at scaling operations and advancing its pipeline through multiple stages of development.
How much funding has ElevateBio raised?
ElevateBio has raised a total of $1.2B across 4 funding rounds:
Series A
$150M
Series B
$170M
Series C
$525M
Series D
$401M
Series A (2019): $150M with participation from Samsara BioCapital, Redmile Group, EcoR1 Capital, MPM Capital, F2 Ventures, and UBS Oncology Impact Fund
Series B (2020): $170M led by EDBI, Samsara BioCapital, Redmile Group, EcoR1 Capital, MPM Capital, F2 Ventures, Surveyor Capital, The Invus Group, and Vertex Ventures
Series C (2021): $525M supported by EDBI, Samsara BioCapital, Redmile Group, EcoR1 Capital, SoftBank Group Corp., ITOCHU, MPM Capital, F2 Ventures, Surveyor Capital, Invus, Fidelity Investments, Matrix Capital Management Company, Emerson Collective, and Vertex Ventures
Series D (2023): $401M featuring Invus, Matrix Capital Management, Woodline Partners, and Emerson Collective
Key Investors in ElevateBio
EcoR1 Capital
EcoR1 Capital is a San Francisco-based investment fund focused on the biotech sector. The company aims to build long-term partnerships with innovative entrepreneurs dedicated to advancing therapeutic innovation and developing new medicines. Their venture portfolio is centered around supporting breakthroughs in biological and chemical discovery, leveraging a deep understanding of the molecular basis of disease. EcoR1 Capital is committed to fostering an environment where innovation thrives and scientific curiosity is encouraged.
MPM Capital
MPM BioImpact manages early-stage venture funds, private/public impact funds and a public equities fund. We convert science into therapeutics to reach the patients that need them most.
Invus
Invus Group is an investment firm specializing in financial advice, investment services, and consulting services. The company was founded in 1985 and is headquartered in New York City, New York.
What's next for ElevateBio?
With substantial enterprise-level funding and a recent strategic investment, ElevateBio is poised for accelerated growth and expansion. The company is likely to focus on advancing its portfolio companies through clinical trials, expanding its operational infrastructure, and forging new strategic partnerships. Continued investment in research and development, coupled with a robust business development strategy, will be critical for realizing its long-term vision of transforming patient care through innovative cell and gene therapies. The company's trajectory suggests a move towards later-stage development and potential commercialization efforts.
See full ElevateBio company page
